- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07942857
Advanced Reticulocyte Parameters in Hemolytic Anemias
Advanced Reticulocyte Parameters as Biomarkers of Erythropoietic Response in Hemolytic Anemias
This cross-sectional study aims to evaluate advanced reticulocyte parameters in patients with thalassemia and sickle cell disease compared with healthy controls.
Study Overview
Status
Conditions
Detailed Description
Hemolytic anemia is characterized by premature destruction of red blood cells. Reticulocytes are immature red blood cells released from the bone marrow, and their assessment reflects erythropoietic activity.
Modern automated hematology analyzers provide advanced reticulocyte parameters including reticulocyte percentage, absolute reticulocyte count, reticulocytes with low, medium and high ribonucleic acid (RNA) content, immature reticulocyte fraction, mean reticulocyte volume, and reticulocyte hemoglobin content.
This observational study will measure these advanced reticulocyte parameters in adult patients with beta-thalassemia, patients with sickle cell disease, and healthy controls.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Kholoud A Ahmed, Resident
- Phone Number: 01553673654
- Email: khloud.18313224@med.aun.edu.eg
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Patients with beta-thalassemia, patients with sickle cell disease, and healthy controls attending Assiut University Hospitals.
Description
Inclusion Criteria:
- - Patients with beta-thalassemia
- Patients with sickle cell disease
- Healthy controls
- Written informed consent
Exclusion Criteria:
- - Other types of anemia
- Recent blood transfusion
Study Plan
How is the study designed?
Design Details
- Observational Models: CASE_CONTROL
- Time Perspectives: CROSS_SECTIONAL
Cohorts and Interventions
Group / Cohort |
|---|
|
Thalassemia Patients
Patients diagnosed with beta-thalassemia. |
|
Sickle Cell Disease Patients
Patients diagnosed with sickle cell disease. |
|
Healthy Controls
Apparently healthy individuals without anemia or hemoglobinopathy. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Immature reticulocyte fraction
Time Frame: Baseline
|
Mean immature reticulocyte fraction measured by automated hematology analyzer (percentage). |
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Absolute reticulocyte count
Time Frame: Baseline
|
Mean absolute reticulocyte count measured by automated hematology analyzer (cells per microliter). |
Baseline
|
|
Reticulocyte percentage
Time Frame: Baseline
|
Mean reticulocyte percentage measured by automated hematology analyzer. |
Baseline
|
|
Reticulocyte hemoglobin content
Time Frame: Baseline
|
Mean reticulocyte hemoglobin content measured by automated hematology analyzer (picograms). |
Baseline
|
|
Mean reticulocyte volume
Time Frame: Baseline
|
Mean reticulocyte volume measured by automated hematology analyzer (femtoliters). |
Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Hisham A Abdel-Baset, prof, Clinical pathology Department, Assiut University Hospitals
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Retic-Params-HA-Assiut-2026
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.